Lexicon Pharmaceuticals (LXRX) Interest & Investment Income (2010 - 2023)
Lexicon Pharmaceuticals (LXRX) posted quarterly Interest & Investment Income of $63000.0 for Q2 2023, up 155.75% year-over-year from $24633.2 in Q2 2022, and down 76.23% quarter-over-quarter from $265000.0 in Q1 2023.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Interest & Investment Income (2010 - 2023) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Interest & Investment Income for 14 consecutive years, with $63000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Interest & Investment Income rose 155.75% year-over-year to $63000.0; the TTM figure through Jun 2023 stood at $50000.0 (up 134.25% YoY), while the FY2022 annual figure was -$418000.0, down 10350.0% from the prior year.
- Interest & Investment Income fell to $63000.0 in Q2 2023 per LXRX's latest filing, from $265000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $776000.0 in Q1 2020 and bottomed at -$548000.0 in Q2 2020.
- Historically, Interest & Investment Income has averaged -$4944.4 across 5 years, with a median of -$3000.0 in 2021.
- Annual changes were most pronounced in 2020 — Interest & Investment Income soared 1624.44% — and 2022, when it plunged 34000.0%.
- Lexicon Pharmaceuticals' Interest & Investment Income stood at $48000.0 in 2019, then plunged by 185.42% to -$41000.0 in 2020, then soared by 87.8% to -$5000.0 in 2021, then soared by 1360.0% to $63000.0 in 2022, then changed by 0.0% to $63000.0 in 2023.
- Business Quant data shows LXRX's Interest & Investment Income at $63000.0 in Q2 2023, $265000.0 in Q1 2023, and $63000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 63,000.00 |
| Mar 31, 2023 | 265,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | -341,000.00 |
| Jun 30, 2022 | -113,000.00 |
| Mar 31, 2022 | -27,000.00 |
| Dec 31, 2021 | -5,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -10,000.00 |
| Mar 31, 2021 | 11,000.00 |
| Dec 31, 2020 | -41,000.00 |
| Sep 30, 2020 | -277,000.00 |
| Jun 30, 2020 | -548,000.00 |
| Mar 31, 2020 | 776,000.00 |
| Dec 31, 2019 | 48,000.00 |
| Sep 30, 2019 | -50,000.00 |
| Jun 30, 2019 | 53,000.00 |
| Mar 31, 2019 | 45,000.00 |
| Dec 31, 2018 | 59,000.00 |
| Sep 30, 2018 | 147,000.00 |